Intravenous Immunoglobulin in the Prevention of Recurrent Spontaneous Abortion: The European Experience

PROBLEM: Clinical trials of the use of intravenous immunoglobulin (IvIg) in the treatment of recurrent spontaneous abortion (RSA) in Europe were reported and discussed. METHOD OF STUDY: A search of the published literature, combined with our own published and unpublished results, was performed. RESU...

Full description

Saved in:
Bibliographic Details
Published in:American journal of reproductive immunology (1989) 1998-02, Vol.39 (2), p.77-81
Main Author: Christiansen, Ole B.
Format: Article
Language:English
Subjects:
Abortion
Abortion, Habitual - immunology
Abortion, Habitual - prevention & control
Abortion, Habitual - therapy
autoimmunity
Biological and medical sciences
Diseases of mother, fetus and pregnancy
Europe
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Humans
Immunoglobulins, Intravenous - therapeutic use
Immunosuppression
immunotherapy
intravenous immunoglobulin
Killer Cells, Natural - immunology
Medical sciences
Pharmacology. Drug treatments
Pregnancy
Pregnancy Outcome
Pregnancy. Fetus. Placenta
recurrent spontaneous abortion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PROBLEM: Clinical trials of the use of intravenous immunoglobulin (IvIg) in the treatment of recurrent spontaneous abortion (RSA) in Europe were reported and discussed. METHOD OF STUDY: A search of the published literature, combined with our own published and unpublished results, was performed. RESULTS: Two placebo‐controlled trials have been concluded in Europe. One trial found high but equal success rates in both the IvIg and the placebo group. Another trial found that IvIg treatment may increase the success rate by 24% compared with placebo but that the result was not statistically significant, which might be due to the small number of patients. Reasons for the diverse results of the two trials were discussed. CONCLUSION: More and larger placebo‐controlled trials of IvIg treatment in RSA are needed before drawing definitive conclusions.
ISSN:1046-7408
8755-8920
1600-0897
DOI:10.1111/j.1600-0897.1998.tb00338.x